ERASA XEP-30 Wins Allure Magazine's Best of Beauty Breakthrough 2015 Award

NEW YORK, NY--(Marketwired - September 24, 2015) - BioMimetic Laboratories, a unit of leading skincare innovator Skyler Brand Ventures, announced that Allure Magazine awarded ERASA XEP-30 its Best of Beauty Breakthrough 2015 Award. Every year Allure's beauty experts sample, research and test thousands of new products on the market. The coveted awards feature the year's most innovative products that utilize advances in technology and science to solve everyday beauty concerns.

ERASA XEP-30 is a revolutionary prestige skincare concentrate whose formulation includes a range of powerful anti-aging ingredients. The key neuropeptide, XEP-30, was created using the power of biomimetic technology exclusively for this product in collaboration with Activen, a leading biotechnology company in the field of cosmetics. Biomimetics is defined as the development of synthetic materials that mimic the structure and function of naturally occurring substances for the purpose of solving complex human challenges, without harming nature.

The awards were announced on the Today Show where the magazine's Editor-in-Chief said, "Erasa is the closest we have gotten yet to Botox and it relaxes the muscles. Your skin feels wonderful without getting paralyzed, and feels gentle and relaxed." The magazine's review continued, "The results are off the charts: namely, a younger-looking face in just two weeks." Allure's top dermatologist reviewer said, "I haven't seen anything else act this quickly. I have heard of formulas attempting to achieve these results, but here we are seeing data that looks quite remarkable."

"This award validates our deep R&D commitment to the development of biomimetic technology in the skincare field. We believe bioimetics or bioidenticals are a tectonic shift in skincare technology and with Erasa we are proving that we are at the leading edge of this technology," stated Jules Zecchino, Founder of Skyler Brand Ventures and the Chief Technology Officer for BioMimetic Laboratories. Jules continued, "XEP-30 is more active and potent than any other neuropeptide on the market, as it mimics the effects of cone snail venom and helps relax the appearance of facial muscles for instant line-smoothing effects."

The award follows BioMimetic Laboratories' announcement in May 2015 that ERASA XEP-30 had achieved remarkably positive results in a 14-day trial in an independent research lab. Independent testing found, on average, a measurable 64% reduction in the appearance of wrinkles, with the top quartile seeing more than a 90% reduction. ERASA XEP-30 was clinically tested by AMA Laboratories, Inc., the cosmetic industry's leading independent testing facility. The commitment to validation using scientific testing instead of user polls is a keystone of product development for all Skyler Brand Venture companies.

BioMimetic Laboratories is a venture-backed company from the portfolio of Skyler Brand Ventures, the premier R&D incubator in the cosmetics industry. Its lead investor is Valmiki Capital Management, a New York based asset manager. Ravi Suria, Valmiki's Managing Partner and BioMimetic Laboratories' founding investor stated, "We were thrilled with clinical results of the first product to come from BioMimetic Laboratories and feel gratified that the industry experts agree with the marketplace's assessment. We invested in Skyler's companies to back the preeminent scientist in the cosmetics industry and are extremely pleased with the technology and products created by Jules Zecchino and his research teams."

Retailing for USD 160.00, ERASA XEP-30 is available exclusively at www.erasaskincare.com, to be followed by a physical presence at select prestigious stores worldwide.